Severe Aplastic Anaemia Working Party (SAAWP)
Study type:
Study number:
84090095
Type of treatment:
Allogeneic
Diseases:
Bone marrow failure
Short title:
HCT outcome old SAA
Primary objective:
To describe the outcome of SAA patients receiving an allogeneic transplant in the period 2010-2020, specifically looking at the impact of age (especially in patients >40 yo) on OS.
Key inclusion criteria:
Country:
All EBMT member countries
Principal investigator:
Antonio Risitano
EBMT Study coordinator:
Brian Piepenbroek
Study coordinator email:
saawp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results